South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Singapore Inflation Stays Muted in May as Core CPI Misses Forecasts Ahead of MAS Review 
Oil Prices Slip as Iran Sanctions Relief and Hormuz Shipping Recovery Ease Supply Concerns 
Yen Near 40-Year Low as USD/JPY Approaches Key 162 Level, Raising Intervention Concerns 
Namyang Dairy Product recently lost two of its leaders - chairman Hong Won Sik and CEO Lee Kwang Bum this week. The two decided to leave over the controversies created by the company’s claim about the effectiveness of its Bulgaris yogurt in fighting COVID-19 symptoms.
The controversy that led to Namyang’s heads exit
Chairman Hong Won Sik stepped down on Tuesday, May 4, and he announced his departure through a press conference. CEO Lee Kwang Bum also left his job on Monday, and their exit came two days after Namyang Dairy’s offices were raided by the authorities as it investigates the COVID-19 false claims.
The two resigned three weeks after the company held a symposium and announced that its Bulgaris yogurt effectively lowers the chance of contracting COVID-19 by at least 77%. However, the South Korean Ministry of Food and Drug Safety called out Namyang for such doubtful claims and immediately launched an investigation.
The public reportedly flocked to grocery stores to buy Namyang’s Bulgaris yogurts, and the company experienced a surge in its shares. This is another reason why a probe has been launched.
New scandal besetting the dairy company
Now, while the yogurt controversy is not yet over, The Korea Times reported that Namyang is facing a new issue. This time it has something to do with a patent infringement violation.
The outlet reported that Namyang’s Inner Care yogurt drink comes with a supplement pill. This is placed in the cap so it can easily be taken when drinking the yogurt. However, the company’s rival, Korea Yakult, that sells MPRO3, which is a probiotics beverage, claimed that the yogurt and pill combination was imitated by Namyang from them.
MPRO3 also comes with a supplement, and Yakult Korea is claiming that they are the originator of this product that was first launched in 2019. On the other hand, Namyang’s Inner Care was only released in February.
With the identical special features between Inner Care and MPRO3, Natural Way, which has the patent rights over Yakult Korea’s design of placing the pill inside the bottle caps, filed a patent lawsuit against Namyang. It was revealed that the filing was done last month.
